Samsara Biocapital
Samsara Biocapital reported 24 stocks worth $1.2B in its 13F filing for Q2 2026, filed Aug 14, 2026. Its largest holdings are SRRK (31.2%), ALMS (14.7%) and MLYS (13.0%). Compared with Q1 2026, the fund opened new positions in ALMR, PBLS and ARTV, added to IVA and RANI, trimmed KLRS, JBIO and ABVX and sold out of PVLA.
Holdings
| # | Stock | Value | Weight | Shares | Change | Shares, 8 qtrs | Held |
|---|---|---|---|---|---|---|---|
| 1 |  SRRK Scholar Rock Hldg Corp | $379M | 31.2% | 6.9M | No change | 8 of 8 | |
| 2 |  ALMS Alumis Inc | $179M | 14.7% | 6.3M | No change | 8 of 8 | |
| 3 |  MLYS Mineralys Therapeutics Inc | $158M | 13.0% | 5.9M | No change | 8 of 8 | |
| 4 |  SEPN Septerna Inc | $105M | 8.7% | 3.1M | No change | 7 of 8 | |
| 5 |  ALMR Alamar Biosciences Inc | $67.2M | 5.5% | 2.5M | New position | 1 of 8 | |
| 6 |  NGNE Neurogene Inc | $54M | 4.4% | 1.7M | No change | 8 of 8 | |
| 7 |  KLRS Kalaris Therapeutics Inc | $52.4M | 4.3% | 12.9M | −67K (−1%) | 6 of 8 | |
| 8 |  SGP Spyglass Pharma Inc | $47M | 3.9% | 2.1M | No change | 2 of 8 | |
| 9 |  STRO Sutro Biopharma Inc | $35.3M | 2.9% | 1.1M | No change | 3 of 8 | |
| 10 |  IVA Inventiva SA | $23.9M | 2.0% | 6.3M | +1.1M (+22%) | 3 of 8 |
Positions at Jun 30, 2026, as reported. Change is against the fund's Q1 2026 filing; weight is the share of the fund's reported stocks.
Sold out
held in Q1 2026, gone in Q2 2026| Stock | Value last quarter | Shares sold |
|---|---|---|
ARCELLX INC | $7M | 61K |
 PVLA Palvella Therapeutics Inc NE | $4.8M | 38K |
Reported value
last 8 quartersThe value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.
Filings for Q2 2026
straight from the SEC| Filed | Form | Quarter | |
|---|---|---|---|
| Aug 14, 2026 | 13F-HR | Q2 2026 | SEC filing ↗ |
Other superinvestors
All hedge fund holdings →Samsara Biocapital 13F FAQ
What does Samsara Biocapital own?
Samsara Biocapital reported 24 stocks worth $1.2B in its 13F filing for Q2 2026, filed Aug 14, 2026. Its largest holdings are SRRK (31.2%), ALMS (14.7%) and MLYS (13.0%). The table above lists every position in the filing (the top 10 without an account).
What did Samsara Biocapital buy and sell in Q2 2026?
Compared with Q1 2026: 4 new positions, 2 added to, 5 trimmed and 2 sold out. New positions include ALMR, PBLS and ARTV. It sold all of PVLA.
When will Samsara Biocapital file its next 13F?
Holdings as of Sep 30, 2026 are due by Nov 16, 2026. The filing appears on this page within minutes of reaching the SEC.
How much is Samsara Biocapital's portfolio worth?
The Q2 2026 filing reports $1.2B in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.